1. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome 
C.J Glueck, M.D., Ping Wang, Ph.D., Suichi Kobayashi, M.D., Harvey Phillips, M.D., Luann Sieve-Smith 
Fertility and Sterility 
Volume 77, Issue 3, Pages (March 2002)
DOI: /S (01)

2. Figure 1
Median weight, body mass index (BMI), fasting serum insulin level, and insulin resistance (IR) in 15 women with the polycystic ovary syndrome before metformin therapy, at their last preconception evaluation during metformin therapy, at their first visit after conception during metformin therapy (4–6 weeks of gestation), and throughout the remainder of their pregnancy during metformin therapy. Paired Wilcoxon tests of difference were done to compare values at baseline with those at prepregnancy during metformin therapy, values at prepregnancy during metformin therapy with those at the first visit after conception during metformin therapy, and values at the first visit after conception during metformin therapy with those during remainder of pregnancy during metformin therapy).
Glueck. Metformin reduces gestational diabetes. Fertil Steril 2002.
Fertility and Sterility  , DOI: ( /S (01) )